Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes

Abstract

Cellular therapies offer novel opportunities for the treatment of type 2 diabetes mellitus (T2DM). The present study evaluated the long-term efficacy and safety of infusion of Wharton's jelly-derived mesenchymal stem cells (WJ-MSC) on T2DM. A total of 61 patients with T2DM were randomly divided into two groups on the basis of basal therapy; patients in group I were administered WJ-MSC intravenous infusion twice, with a four-week interval, and patients in group II were treated with normal saline as control. During the 36-month follow-up period, the occurrence of any adverse effects and the results of clinical and laboratory examinations were recorded and evaluated. The lack of acute or chronic adverse effects in group I was consistent with group II.. Blood glucose, glycosylated hemoglobin, C-peptide, homeostasis model assessment of pancreatic islet β-cell function and incidence of diabetic complications in group I were significantly improved, as compared with group II during the 36-month follow-up. The results of the present study demonstrated that infusion of WJ-MSC improved the function of islet β-cells and reduced the incidence of diabetic complications, although the precise mechanisms are yet to be elucidated. The infusion of WJ-MSC may be an effective option for the treatment of patients with type 2 diabetes.

Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis

“…Patient populations were diverse and included cardiovascular (12 trials, n = 612 patients) [21,24À27,29,37,40,42,44,49,58], neurological (10 trials, n = 242 patients) [30À32, 36,45,48,57,62,65,69], renal (three trials, n = 177 patients) [55,63,67], liver (seven trials, n = 404 patients) [35,43,47,53,54,59,66], respiratory (three trials, n = 134 patients) [18,23,68] and endocrine diseases (four trials, n = 169 patients) [22,28,39,50], hematological/oncological malignancies (five trials, n = 318 patients) [33,34,41,46,71], immune deficient or inflammatory conditions (nine trials, n = 544 patients) [20,38,51,52,60,61,64,70,72], general frailty (one trial, n = 30 patients) [56], and severe sepsis in severely neutropenic patients with hematologic malignancies (one trial, n = 30 patients) [19].…”

“…With respect to MSC preparation and administration, of the 55 included RCTs, 31 (56¢4%) examined bone marrow [19,21-27,29-34,36,39,41-43,45,47,53,55À59,61,66,68,71], 16 (29¢1%) umbilical cord [28,35,38,40,44,46,[48][49][50][51][52]54,60,63,65,72], four (7¢3%) adipose-derived MSCs [18,20,62,64], two (3¢6%) placenta-derived cells [69,70]; and in two RCT (3¢6%) the source of MSCs was unclear [37,67]. See Supplementary Table 1 [33,34,41,67].…”

Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus

“…Liu et al showed that WJ-MSC transplantation significantly decreased the levels of glucose, improved C-peptide levels, and improved beta cell function, all without any adverse effects (Liu et al, 2014). , Hu et al (2016 reported the long-term efficacy and safety of infusion of WJ-MSC on T2D in a study of61 patients with T2DM. After the 36-month follow-up period, infusion of WJ-MSC not only improved function of islet β-cells but reduced diabetic complications (Hu et al, 2016).…”

“…, Hu et al (2016 reported the long-term efficacy and safety of infusion of WJ-MSC on T2D in a study of61 patients with T2DM. After the 36-month follow-up period, infusion of WJ-MSC not only improved function of islet β-cells but reduced diabetic complications (Hu et al, 2016). Based on these results, we investigated the use of autologous expanded adipose derived stem cells (ADSCs) for transplantation to treat T2D patients.…”

Small Molecule-Induced Pancreatic β-Like Cell Development: Mechanistic Approaches and Available Strategies

“…Evolution from research to preclinical studies, and lastly, to clinical trials is occurring in many fields (Table 4). Some researchers have administered a WJ-MSC infusion to T2DM patients, resulting in the improvement of β-cell function and reducing the severity of complications experienced by diabetic patients [121].…”